Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Virginie Vitrat

Showing results (11-20 of 23) with videos related to

Pageof 3
Sort By:
European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology|May 28, 2024
Effectiveness and safety of cefazolin versus cloxacillin in endocarditis due to methicillin-susceptible Staphylococcus spp.: a multicenter propensity weighted cohort studyAnne-Laure Destrem, Alexis Maillard, Mathieu Simonet, et al.
Infectious Diseases Now|February 10, 2025
Real-world use, effectiveness, and safety of ceftazidime-avibactam: Results of the French cohort OZAVIELionel Piroth, Virginie Vitrat, Vincent Le Moing, et al.
Age and Ageing|March 5, 2014
Aminoglycosides use in patients over 75 years oldThibaut Fraisse, Claudine Gras Aygon, Marc Paccalin, et al.
BMC Health Services Research|May 17, 2023
Infectious disease hotlines to provide advice to general practitioners: a prospective studyAnna Luce Sette, Patrice François, Philippe Lesprit, et al.
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases|May 11, 2024
Exclusive oral antibiotic treatment for hospitalized community-acquired pneumonia: a post-hoc analysis of a randomized clinical trialAurélien Dinh, Clara Duran, Jacques Ropers, et al.
JAMA Network Open|October 15, 2021
Factors Associated With Treatment Failure in Moderately Severe Community-Acquired Pneumonia: A Secondary Analysis of a Randomized Clinical TrialAurélien Dinh, Clara Duran, Jacques Ropers, et al.
Lancet (London, England)|March 28, 2021
Discontinuing β-lactam treatment after 3 days for patients with community-acquired pneumonia in non-critical care wards (PTC): a double-blind, randomised, placebo-controlled, non-inferiority trialAurélien Dinh, Jacques Ropers, Clara Duran, et al.
The Lancet. Infectious Diseases|January 20, 2024
Efficacy and safety of an early oral switch in low-risk Staphylococcus aureus bloodstream infection (SABATO): an international, open-label, parallel-group, randomised, controlled, non-inferiority trialAchim J Kaasch, Luis Eduardo López-Cortés, Jesús Rodríguez-Baño, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|July 20, 2019
Ceftazidime, Carbapenems, or Piperacillin-tazobactam as Single Definitive Therapy for Pseudomonas aeruginosa Bloodstream Infection: A Multisite Retrospective StudyTanya Babich, Pontus Naucler, John Karlsson Valik, et al.
International Journal of Antimicrobial Agents|November 27, 2019
Risk factors for mortality among patients with Pseudomonas aeruginosa bacteraemia: a retrospective multicentre studyTanya Babich, Pontus Naucler, John Karlsson Valik, et al.
Pageof 3

Showing results (11-20 of 23) with videos related to

Sort By:
Pageof 3
European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology|May 28, 2024
Effectiveness and safety of cefazolin versus cloxacillin in endocarditis due to methicillin-susceptible Staphylococcus spp.: a multicenter propensity weighted cohort studyAnne-Laure Destrem, Alexis Maillard, Mathieu Simonet, et al.
Infectious Diseases Now|February 10, 2025
Real-world use, effectiveness, and safety of ceftazidime-avibactam: Results of the French cohort OZAVIELionel Piroth, Virginie Vitrat, Vincent Le Moing, et al.
Age and Ageing|March 5, 2014
Aminoglycosides use in patients over 75 years oldThibaut Fraisse, Claudine Gras Aygon, Marc Paccalin, et al.
BMC Health Services Research|May 17, 2023
Infectious disease hotlines to provide advice to general practitioners: a prospective studyAnna Luce Sette, Patrice François, Philippe Lesprit, et al.
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases|May 11, 2024
Exclusive oral antibiotic treatment for hospitalized community-acquired pneumonia: a post-hoc analysis of a randomized clinical trialAurélien Dinh, Clara Duran, Jacques Ropers, et al.
JAMA Network Open|October 15, 2021
Factors Associated With Treatment Failure in Moderately Severe Community-Acquired Pneumonia: A Secondary Analysis of a Randomized Clinical TrialAurélien Dinh, Clara Duran, Jacques Ropers, et al.
Lancet (London, England)|March 28, 2021
Discontinuing β-lactam treatment after 3 days for patients with community-acquired pneumonia in non-critical care wards (PTC): a double-blind, randomised, placebo-controlled, non-inferiority trialAurélien Dinh, Jacques Ropers, Clara Duran, et al.
The Lancet. Infectious Diseases|January 20, 2024
Efficacy and safety of an early oral switch in low-risk Staphylococcus aureus bloodstream infection (SABATO): an international, open-label, parallel-group, randomised, controlled, non-inferiority trialAchim J Kaasch, Luis Eduardo López-Cortés, Jesús Rodríguez-Baño, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|July 20, 2019
Ceftazidime, Carbapenems, or Piperacillin-tazobactam as Single Definitive Therapy for Pseudomonas aeruginosa Bloodstream Infection: A Multisite Retrospective StudyTanya Babich, Pontus Naucler, John Karlsson Valik, et al.
International Journal of Antimicrobial Agents|November 27, 2019
Risk factors for mortality among patients with Pseudomonas aeruginosa bacteraemia: a retrospective multicentre studyTanya Babich, Pontus Naucler, John Karlsson Valik, et al.
Pageof 3